Roic.ailogo
Powered by AI
US stock · Healthcare sector · Diagnostics & Research
Company Logo

Aclaris Therapeutics, Inc.

ACRSNASDAQ

7.95

USD
+0.06
(+0.76%)
Market Closed
-5.68P/E
-5Forward P/E
-0.27P/E to S&P500
546.357MMarket CAP
- -Div Yield
SummaryFinancialsTranscriptsMonitoringClassic View
Upcoming Earnings
8 May-12 May
Shares Short
2/28/23
3.3M
Short % of Float
5.14%
Short % of Shares Outs.
4.95%
% Held by Insiders
3.15%
% Held by Institutions
100.44%
Beta
0.61
PEG Ratio
-0.06
52w. high/low
18.96/5.77
Avg. Daily Volume
1.00M
Return %
Stock
S&P 500
1 year
(51.33)
(11.55)
3 years
786.52
64.96
5 years
(55.35)
44.15
Scale: |
High
Low
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
33.88
10.99
31.80
14.12
33.25
21.32
26.25
6.15
8.19
0.74
7.95
0.70
30.38
5.65
18.96
9.26
18.54
5.77
Currency: USD
- -
- -
- -
- -
- -
- -
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Revenue per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.06
0.31
0.10
0.15
0.16
0.46
Earnings per share
- -
- -
- -
- -
- -
- -
(0.49)
(0.92)
(3.37)
(2.25)
(2.44)
(4.03)
(3.90)
(1.20)
(2.14)
(1.33)
FCF per share
- -
- -
- -
- -
- -
- -
(0.46)
(0.87)
(3.42)
(1.63)
(1.99)
(3.10)
(2.37)
(0.92)
(1.23)
(1.04)
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
- -
- -
- -
- -
- -
- -
- -
0.05
0.08
0.01
0.04
0.04
0.04
0.01
0.01
0.01
Book Value per sh.
- -
- -
- -
- -
- -
- -
(0.86)
(2.24)
15.15
7.91
8.02
6.54
1.69
0.89
4.64
3.03
Comm.Shares outs.
- -
- -
- -
- -
- -
- -
11
9
6
21
28
33
41
43
43
65
Avg. annual P/E ratio
- -
- -
- -
- -
- -
- -
- -
- -
(6.0)
(9.6)
(11.0)
(4.2)
(1.0)
(2.0)
(8.8)
(11.1)
P/E to S&P500
- -
- -
- -
- -
- -
- -
- -
- -
(0.3)
(0.4)
(0.5)
(0.2)
(0.0)
(0.1)
(0.3)
(0.5)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
10
4
6
7
30
Operating margin
- -
- -
- -
- -
- -
- -
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(4,303.2)%
(1,341.9)%
(2,627.3)%
(785.4)%
(1,327.1)%
(302.0)%
Depreciation (m)
- -
- -
- -
- -
- -
- -
0
0
0
0
0
2
6
1
1
1
Net profit (m)
- -
- -
- -
- -
- -
- -
(5)
(9)
(21)
(48)
(69)
(133)
(161)
(51)
(91)
(87)
Income tax rate
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.6%
- -
- -
0.4%
- -
- -
Net profit margin
- -
- -
- -
- -
- -
- -
(Infinity)%
(Infinity)%
(Infinity)%
(Infinity)%
(4,071.5)%
(1,315.4)%
(3,817.2)%
(787.0)%
(1,344.0)%
(292.1)%
Working capital (m)
- -
- -
- -
- -
- -
- -
13
15
85
132
187
152
61
43
(23)
208
Long-term debt (m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
30
- -
11
- -
- -
Equity (m)
- -
- -
- -
- -
- -
- -
(9)
(21)
93
169
225
215
70
38
197
198
ROIC
- -
- -
- -
- -
- -
- -
(37.8)%
(53.5)%
(22.2)%
(28.3)%
(29.7)%
(53.5)%
(212.7)%
(91.2)%
(39.8)%
(37.4)%
Return on capital
- -
- -
- -
- -
- -
- -
(36.9)%
(49.0)%
(21.9)%
(27.3)%
(28.9)%
(48.2)%
(164.1)%
(72.3)%
(36.2)%
(34.1)%
Return on equity
- -
- -
- -
- -
- -
- -
57.1%
41.0%
(22.2)%
(28.4)%
(30.4)%
(61.7)%
(230.8)%
(135.5)%
(46.0)%
(44.0)%
Plowback ratio
- -
- -
- -
- -
- -
- -
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Capital Structure
23 Feb · 2023 | Q4
All numbers in millions
Total liabilities
$ 57
Total assets
$ 255
Long-term debt
$ - -
Cash and equiv.
$ 45
Goodwill
$ - -
Retained earnings
$ (87)
Common stock
67
Enterprise Value
$ 501
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
54
27
218
Receivables
1
- -
0
Inventory
- -
- -
- -
Other
3
(22)
35
Current assets
57
- -
230
Acc. Payable
5
- -
10
Debt due
1
- -
1
Other
9
23
11
Current liabilities
15
23
22
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
340.05%
84.90%
- -
Cash flow
28.84%
(0.29)%
47.99%
Earnings
(4.35)%
6.73%
55.68%
Dividends
- -
- -
- -
Book value
0.14%
77.66%
0.33%
Insider Trading
Type
Shares
Date
Manion Douglas J.
Purchase
6,300
03/17/23
Manion Douglas J.
Purchase
6,500
03/09/23
Walker Neal
Sale
30,240
03/03/23
Monahan Joseph
Sale
16,037
03/03/23
Balthaser Kevin
Sale
894
03/03/23
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
1
2
1
2
6
2021
2
2
2
2
7
2022
1
2
19
8
30
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
(0.37)
(0.27)
(0.25)
(0.31)
(1.20)
2021
(0.68)
(0.43)
(0.50)
(0.54)
(2.14)
2022
(0.29)
(0.31)
(0.31)
(0.42)
(1.33)
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Diagnostics & Research
CEO:
Dr. Douglas J. Manion Frcp(C), M.D.
Full-time employees:
72
City:
Wayne
Address:
640 Lee Road
IPO:
Oct 7, 2015
CIK:
0001557746
Website:
aclaristx.com
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.